-+ 0.00%
-+ 0.00%
-+ 0.00%

ENHERTU® APPROVED IN THE EU AS ADJUVANT TREATMENT FOR PATIENTS WITH RESIDUAL DISEASE AFTER NEOADJUVANT TREATMENT FOR HER2 POSITIVE EARLY BREAST CANCER

Reuters·10/27/2026 07:30:00

Please log in to view news